AstraZeneca cannot provide further details on the patient’s unexplained illness as well as Oxford University, which is currently running its own study. Oxford said disclosing any further information would violate participant confidentiality.
Earlier in July, both the AstraZeneca and Oxford trials were halted after reports of a participant experiencing neurological symptoms. It was later found that the participant was diagnosed with multiple sclerosis and their symptoms had no relation to the vaccine.
AstraZeneca is “committed to the safety of trial participants”
On Friday, study subjects were given an informational sheet regarding concerns that the vaccine was damaging to participants. The document indicated that researchers conducted safety reviews following reports that participants were experiencing neurological symptoms such as “changed sensation” or weakness in the limbs.
Oxford also posted the document on its website.
The Oxford study includes over 18,000 patients while AstraZeneca’s U.S. trials prior to the pause involved 30,000 participants.
